CRISPR Therapeutics (NASDAQ:CRSP) Stock, Quote.Headers.trade-ideas

CRISPR Therapeutics

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for to treat Type 1 diabetes.

Dexcom G6 on body

Long Ideas

News

Markets

Media

Trading Ideas

COST

CRSP

DLTR

DXCM

The &#34;Mad Money&#34; host says Dexcom had &#34;a real bad miss... they still really haven&#39;t fully explained why that is.&#34;

Jim Cramer: This Energy Stock Is A Buy, Stay Away From DexCom

cathie-wood-bz-ark

Equities

ARKG

ARKK

ARKW

COIN

DKNG

NVDA

PATH

PLTR

ROKU

SHOP

TSLA

TWST

In a recent letter to investors, Cathie Wood, the CEO of ARK Invest, highlighted the potential of the company&#39;s flagship fund, ARK Innovation ETF, despite its recent underperformance.

Cathie Wood Touts Palantir, Coinbase And Roku As ARK&#39;s Flagship Fund Shifts Focus From Mag 6 Amid &#39;Whiff&#39; Of Lower Interest Rates

Cathie Wood Ark Photo courtesy Benzinga YouTube and Unsplash

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

ETFs

$BTC

ARKF

MRNA

PINS

On Tuesday, Cathie Wood-led Ark Invest made a significant move by offloading a substantial number of shares in Coinbase Global Inc (NASDAQ:COIN), despite Bitcoin (CRYPTO: BTC) reaching new 

Cathie Wood&#39;s Ark Invest Keeps Dumping Coinbase Shares Amid Bitcoin, Crypto Buzz

CRISPR Therapeutics AG

<p>Semiconductor stocks especially the ones linked to artificial intelligence technology led by <strong>Nvidia Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), <strong>Broadcom Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), <strong>Advanced Micro Devices, Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), <strong>Arm Holdings plc </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>), <strong>Super Micro Computer, Inc </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) picked up after the U.S. Federal Reserve cut <a target="_blank" href="https://in.benzinga.com/markets/equities/24/09/40932103/it-stocks-on-the-rise-after-u-s-fed-cuts-interest-rate" rel="noreferrer noopener">benchmark interest rate</a> to spur growth.</p>
<p>The U.S. Federal Reserve decided to cut its benchmark interest rate by 50 basis points in a first since 2020, setting the interest rate at 4.75% and 5%. The cut is expected to boost discretionary spending by the companies.</p>
<p>The rate cut will be a welcome move, as semiconductor companies have invested heavily in Big Tech (including <strong>Microsoft Corp</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>), <strong>Amazon.Com Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), <strong>and Google </strong>parent <strong>Alphabet Inc </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)) spending on their artificial intelligence ambitions, which entail substantial capital expenditures.</p>
<p><strong><em>Also Read:</em></strong><em> <a target="_blank" href="https://www.benzinga.com/news/24/09/40926422/super-micro-poised-for-expansion-as-gross-margin-concerns-ease-internal-control-risks-priced-in-anal" rel="noreferrer noopener">Super Micro Poised for Expansion as Gross Margin Concerns Ease, Internal Control Risks Priced In: Analyst</a></em></p>
<p>The semiconductor companies are also under pressure due to the U.S. sanctions on China, a crucial market. Therefore, U.S. investors and the semiconductor chiefs closely watch the agenda of the next President, expecting a softer stance on China.</p>
<p>As per <a target="_blank" href="https://www.benzinga.com/news/24/09/40790177/harris-vs-trump-us-stocks-face-growing-risks-amid-economic-uncertainty-and-upcoming-presidential-ele" rel="noreferrer noopener">a CNBC survey</a>, Republican candidate Donald Trump appeared to be an investor favorite as the S&amp;P 500 and Nasdaq noted significant upside during Trump's tenure as President.</p>
<p>However, the current Biden administration has started doling out semiconductor grants to the companies to consolidate its position.</p>
<p>Contract chipmaker <strong>Taiwan Semiconductor Manufacturing Co</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), a crucial AI chip supplier for U.S. semiconductor companies, remains hugely invested in <a target="_blank" href="https://www.benzinga.com/news/24/09/40928754/what-has-taiwan-semiconductor-stock-done-since-nvidia-earnings" rel="noreferrer noopener">its Arizona fab construction</a> to produce AI chips after bagging U.S. chip subsidies. It recently secured two smartphone chip deals from Google and Apple.</p>
<p><strong>Price Actions:</strong> NVDA stock is up 3.16% at $116.95 premarket at last check Thursday. AMD is up 3.74% at $153.84, AVGO is up 3.45% at $167.25, SMCI is up 3.00% at $450.00, TSM is up 2.80% at $171.97, INTC is up 2.31% at $21.25, ARM is up 3.78% at $143.59.</p>
<p><em>Photo via Shutterstock</em></p>


Government

Regulations

Movers

Tech

AMZN

AVGO

GOOG

GOOGL

INTC

MSFT

SMCI

What's Going On With AI Related Stocks Nvidia, AMD, Broadcom And Super Micro On Thursday?

<p><i>Zeta Marketing Platform brings next-generation AI capabilities to enhance Yahoo marketing and amplify precision and reach for brands</i></p>
<p>Zeta Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>), the AI-powered marketing Cloud, and Yahoo, a global media and tech company that serves as the trusted guide to the internet for hundreds of millions of people globally, today announced plans to migrate Yahoo's email marketing to the Zeta Marketing Platform (ZMP). Additionally, Zeta's Data Cloud is now interoperable with Yahoo ConnectID, enabling Yahoo DSP users to seamlessly activate audiences to deliver higher returns on investment.</p>


ZETA

Zeta Global And Yahoo Announces Plans To Migrate Yahoo's Email Marketing To The Zeta Marketing Platform, Zeta's Data Cloud Is Now Interoperable With Yahoo ConnectID, Enabling Yahoo DSP Users To Seamlessly Activate Audiences To Deliver Higher Returns On Investment

Management

GRYP

Gryphon Digital Mining Terminates Robby Chang As CEO And President, Appoints Steve Gutterman As New CEO Effective September 17, 2024

<p>JP Morgan  analyst Matthew Boss   downgrades Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) from Neutral to Underweight and raises the price target from $89 to $95.</p>


Downgrades

Price Target

Analyst Ratings

FIVE

JP Morgan Downgrades Five Below to Underweight, Raises Price Target to $95

<p><i>INAQ's Special Meeting of Stockholders to Approve the Business Combination Scheduled to be Held on October 14, 2024</i></p>
<p>CORNELIUS, N.C. and NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Alpha Modus Corp. ("Alpha Modus"), a technology company with a core focus on artificial intelligence in retail, and Insight Acquisition Corp. ("Insight") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAQ#NASDAQ">INAQ</a>), a publicly traded special purpose acquisition company, announced today that the U.S. Securities and Exchange Commission ("SEC") has declared effective the registration statement on Form S-4 (as amended, the "Registration Statement") filed with the SEC related to the previously announced business combination (the "Business Combination"). Insight has also filed with the SEC the definitive proxy statement for its special meeting of stockholders (the "Special Meeting"), to, among other things, approve the Business Combination.<br /><br />&nbsp;</p>
<p>Upon closing of the Business Combination, which is subject to stockholder approval, the combined company will operate as "Alpha Modus Holdings, Inc." and its common stock and warrants are expected to commence trading on the Nasdaq Global Market ("Nasdaq") under the tickers "AMOD" and "AMODW", respectively, shortly thereafter.</p>
<p>For additional details regarding the Business Combination, please see the sources described below under, "Important Information About the Proposed Business Combination and Where to Find It".</p>


INAQ

Alpha Modus And Insight Acquisition Corp. Announce Effectiveness Of Form S-4 Registration Statement For Proposed Business Combination,  Expects To Commence Trading On The Nasdaq Global Market Under The Tickers "AMOD"

<p>Leerink Partners  analyst Mani Foroohar   reiterates 4D Molecular Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) with a Outperform and lowers the price target from $40 to $36.</p>


Reiteration

FDMT

Leerink Partners Reiterates Outperform on 4D Molecular Therapeutics, Lowers Price Target to $36

<p>RBC Capital  analyst Luca Issi   reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Outperform and maintains $300 price target.</p>


ALNY

RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $300 Price Target

<p>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) PersonalAIze and RenovaroCube are proud to announce a strategic partnership to develop, validate, and commercialize&nbsp;Cube's&nbsp;AI-driven, multi-omic&nbsp;platform for&nbsp;early detection of cancer and other diseases. This strategic partnership aims to provide services to many AI companies and healthcare systems while also creating the next generation of medical diagnostics through cutting-edge AI by driving greater accuracy, transparency, and trust in healthcare solutions.</p>


Biotech

General

RENB

PersonalAIze And RenovaroCube Announce A Strategic Partnership To Develop, Validate, And Commercialize Cube's AI-Driven Platform For Early Detection Of Cancer And Other Diseases

TNDM

Tandem's t:slim X2 Insulin Pump Now Compatible With Lyumjev Ultra-Rapid Acting Insulin In The European Union

<p>Jewett-Cameron Trading Company Ltd. ("Jewett-Cameron") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JCTCF#NASDAQ">JCTCF</a>), a company committed to innovative products that enrich outdoor spaces, today announced it has retained one of the industry's leading investor relations firms, Lytham Partners, LLC, to lead a strategic investor relations and shareholder communication program.<br /><br />&nbsp;</p>
<p>For more than 20 years, Lytham Partners has cultivated a highly diverse network of institutional investors, while creating a framework of best practices in all aspects of corporate and shareholder communications. In addition to their relationships with many of the most respected institutional investors, Lytham Partners has spent the past two decades creating an integrated platform enabling far-reaching exposure to investors in a consistent and in-depth format including the Lytham Partners Investor Conference Series. This platform includes a communications and positioning approach that is achieved through various means, including via press releases, conference calls, investor presentations, profiles, corporate access, and websites.</p>


JCTCF

Jewett-Cameron Announces It Has Retained An Investor Relations Firms, Lytham Partners, LLC, To Lead A Strategic Investor Relations And Shareholder Communication Program

<p>RealVision&#8217;s chief crypto analyst <strong>Jamie Coutts</strong> shared his insights on the current crypto market downturn, hinting at a potential bullish shift based <a href="https://www.benzinga.com/money/what-you-need-to-know-about-technical-analysis">on technical indicators</a>.</p>
<p><strong>What Happened:</strong> In a detailed <a href="https://x.com/Jamie1Coutts/status/1836192082127655274">thread</a> of <strong>X</strong>, Coutts highlighted a 55% pullback of the top 200 cryptocurrencies equally weighed over the past six months. </p>
<p>He noted that despite the downtrend, the risk/reward ratio is favorable for adding to select assets at these levels. Coutts also pointed out a sharp move higher on the altseason indicator, suggesting a potential end to the bearish thrust.</p>
<p>He further explained that a return to a bullish regime could be indicated when more than 45% of assets trade above their 200-day moving average. Currently, only 11% of assets are above this mark.</p>
<p>Coutts believes that traders will need the price to break out of downtrends, but for allocators, current price levels are desirable to add as the risk/reward is favorable.</p>
<p><figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure></p>
<p><strong>Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40926060/bitcoin-is-in-for-a-massive-bull-run-if-this-2020-pattern-repeats-analyst-says">Bitcoin Is In For A &#8216;Massive Bull Run&#8217; If This 2020 Pattern Repeats, Analyst Says</a></strong></p>
<p><strong>Why It Matters:</strong> Coutts' analysis contrasts the last months of persistent sideways trading. The analyst sees early signs of a potential reversal, similar to that in Q3 2023.</p>
<p>He also emphasized the role of liquidity in driving the market, stating that it has now turned decisively bullish and is <a href="https://x.com/Jamie1Coutts/status/1824053788027851175">likely</a> to push <strong>Bitcoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) higher. </p>
<p>Despite the price decline over the past six months, key crypto ecosystem fundamental metrics have performed well, with addresses up by 73% and rising transactions.</p>
<p>While acknowledging the current bearish price action, Coutts suggested that the final throes of the big flush of the past months could make Q4 critical for 12-month forward returns for allocators.</p>
<p><strong>What&#8217;s Next</strong>: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.</p>
<p><strong>Read Next:&nbsp;</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40919168/ethereum-co-founder-says-donald-trump-is-certainly-the-favorite-over-kamala-harris-for-cry">Ethereum Co-Founder Says Donald Trump Is &#8216;Certainly The Favorite&#8217; Over Kamala Harris For Crypto</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


$ETH

Raoul Pal's Chief Crypto Analyst Says The Bull Market Is Back When This Indicator Hits 45% (It's Now At 11%)

<p>Iconic Golf Simulator Company Awards Local Entrepreneurs&nbsp;Opportunity to Develop 80 New Centers</p>
<p>CHICAGO, Sept. 19, 2024 /PRNewswire/ -- TruGolf Links Franchising, LLC ("TruGolf"), owned by TruGolf Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>), a leading provider of golf simulator software and hardware, announced today the signing of its second regional development deal. Led by experienced entrepreneurs Bob Early and Ron&nbsp;Rzansa, the deal spans the surrounding Chicago suburbs and into the northwest region of Indiana. The agreement includes the rights to open 80 locations, either owned or franchised, with plans to hit the markets aggressively and create close ties within local communities across the region.</p>


TRUG

TruGolf Links Announces The Signing Of Its Second Regional Development Deal, Includes The Rights To Open 80 Locations, Either Owned Or Franchised, With Plans To Hit The Markets Aggressively And Create Close Ties Within Local Communities Across The Region

<p>Leerink Partners  analyst Joseph Schwartz   maintains Applied Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>) with a Outperform and raises the price target from $11 to $14.</p>


APLT

Leerink Partners Maintains Outperform on Applied Therapeutics, Raises Price Target to $14

<p>Jefferies  analyst Julien Dumoulin-Smith   initiates coverage on NextEra Energy Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEP#NYSE">NEP</a>) with a Buy rating and announces Price Target of $28.</p>


Initiation

Jefferies Initiates Coverage On NextEra Energy Partners with Buy Rating, Announces Price Target of $28

WIIM

PLUG

Plug Power shares are trading higher after the company launched an equipment lease financing platform.

<p>In the preceding three months, 5 analysts have released ratings for Regal Rexnord (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRX#NYSE">RRX</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $195.6, a high estimate of $213.00, and a low estimate of $180.00. This current average has increased by 0.31% from the previous average price target of $195.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726750871_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The perception of Regal Rexnord by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Dankert</td>
<td>Loop Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Joe Ritchie</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$195.00</td>
<td>$176.00</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$213.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Jeffrey Hammond</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$210.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Regal Rexnord. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Regal Rexnord compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Regal Rexnord's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Regal Rexnord's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RRX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Regal Rexnord analyst ratings.</strong></a></p>
<h2>Delving into Regal Rexnord's Background</h2>
<p>Regal Rexnord Corp is in the engineering and manufacturing of industrial powertrain solutions, power transmission components, electric motors and electronic controls, air moving products, and specialty electrical components and systems, serving customers around the world. The four operating segments include Commercial Systems, Industrial Systems, Climate Solutions, and Motion Control Solutions.</p>
<h3>Understanding the Numbers: Regal Rexnord's Finances</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Regal Rexnord's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately <strong>-12.5%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Regal Rexnord's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>4.04%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>0.99%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Regal Rexnord's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.42%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Regal Rexnord's debt-to-equity ratio surpasses industry norms, standing at <strong>0.93</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Closer Look at 5 Analyst Recommendations For Regal Rexnord

<p>Analysts' ratings for Vista Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTO#NYSE">VSTO</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $41.17, with a high estimate of $43.00 and a low estimate of $40.00. This current average reflects an increase of 1.91% from the previous average price target of $40.40. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726750863_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Vista Outdoor. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt Koranda</td>
<td>Roth MKM</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Eric Wold</td>
<td>B. Riley Securities</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$43.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Rommel Dionisio</td>
<td>Aegis Capital</td>
<td>Announces</td>
<td>Hold</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Mark Smith</td>
<td>Lake Street</td>
<td>Raises</td>
<td>Hold</td>
<td>$40.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Matt Koranda</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$42.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Matt Koranda</td>
<td>Roth MKM</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Vista Outdoor. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Vista Outdoor compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Vista Outdoor's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Capture valuable insights into Vista Outdoor's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/VSTO/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Vista Outdoor analyst ratings.</strong></a></p>
<h2>Discovering Vista Outdoor: A Closer Look</h2>
<p>Vista Outdoor Inc designs, develops, and manufactures outdoor sports and recreation products, and is domiciled in the United States. The company operates through the following reportable segments: the Kinetic Group, Revelyst Outdoor Performance, Revelyst Adventure Sports, and Revelyst Precision Sports Technology. The majority of the company's revenue is generated from its Kinetic Group segment which consists of its ammunition brands and provides ammunition used for training, hunting, target shooting, and personal protection.</p>
<h3>Vista Outdoor's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Vista Outdoor's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately <strong>-7.09%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Vista Outdoor's net margin is impressive, surpassing industry averages. With a net margin of <strong>8.87%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Vista Outdoor's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>4.94%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Vista Outdoor's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>2.4%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Vista Outdoor's debt-to-equity ratio is below the industry average. With a ratio of <b>0.63</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


VSTO

Beyond The Numbers: 6 Analysts Discuss Vista Outdoor Stock

<p>On CNBC's <a href="https://www.cnbc.com/video/2024/09/18/final-trades-energy-transfer-trade-desk-alphabet-and-general-motors.html">&#8220;Halftime Report Final Trades,&#8221;</a> <strong>Jim Lebenthal</strong> said <strong>General Motors Company</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) benefits from rate cuts.</p>
<p>General Motors, last week, agreed to explore collaboration with Hyundai Motor and expand its partnership with EVgo by installing 400 fast-charging stalls at key locations in major U.S. metropolitan areas. Additionally, the company is reportedly in talks to buy Chinese batteries made in the U.S. through its <a href="https://www.benzinga.com/markets/penny-stocks/24/09/40905775/gm-and-hyundai-join-forces-to-boost-competitiveness-and-improve-efficiency">partnership with Japan's TDK</a>.</p>
<p><strong>Bryn Talkington</strong> of Requisite Capital Management named <strong>Energy Transfer LP</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>), an energy play, which is up 16% year-to-date. The company also has a dividend<a href="https://www.benzinga.com/quote/ET/analyst-ratings"> yield of 8%, she added</a>.</p>
<p>On Wednesday, <strong>UBS</strong> analyst <strong>Shneur Gershuni</strong> maintained Energy Transfer with a Buy rating and raised the price target from $22 to $23.</p>
<p><em>Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a></em></p>
<p><strong>Joseph M. Terranova</strong> of Virtus Investment Partners said <strong>The Trade Desk, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>), is pushing back to its Nov. 2021 all-time high level.</p>
<p>On Sept. 13, Wedbush analyst Scott Devitt maintained Trade Desk with an Outperform rating and raised the price target from $110 to $115.</p>
<p><strong>Stephen Weiss</strong> of Short Hills Capital Partners said <strong>Alphabet Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) is still undervalued.</p>
<p>Alphabet Google won its appeal against the European Commission&#8217;s €1.49 billion ($1.66 billion) antitrust fine for anticompetitive practices involving its online search advertising business. Luxembourg-based General Court delivered a reprieve to Google, nullifying the line about the $1.66 billion penalty in the European Commission&#8217;s five-year-old <a href="https://www.benzinga.com/24/09/40915828/google-wins-1-7b-eu-antitrust-fine-appeal-over-5-year-old-online-search-advertising-case">order against the search giant, reported Reuters.</a></p>
<p><strong>Price Action:</strong></p>
<ul>
<li>Energy Transfer gained 0.6% to close at $16.11 during Wednesday's session.</li>
<li>Trade Desk shares gained 2.1% to settle at $108.02 on Wednesday.</li>
<li>Alphabet shares gained 0.3% to close at $160.81 during Wednesday's session.</li>
<li>General Motors shares gained 2.4% to settle at $48.66 on Wednesday.</li>
</ul>
<p><strong>Check This Out: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/24/09/40927530/coinbase-global-electronic-arts-and-2-other-stocks-executives-are-selling">Coinbase Global, Electronic Arts And 2 Other Stocks Executives Are Selling</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


General Motors, Alphabet, Trade Desk And An Energy Stock On CNBC's 'Final Trades'

<p>Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Kodiak Gas Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGS#NYSE">KGS</a>) in the last three months.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Kodiak Gas Services and provided 12-month price targets. The average target is $33.0, accompanied by a high estimate of $35.00 and a low estimate of $29.00. This current average reflects an increase of 6.45% from the previous average price target of $31.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726750827_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The perception of Kodiak Gas Services by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sebastian Erskine</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Buy</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Selman Akyol</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Theresa Chen</td>
<td>Barclays</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$29.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Kodiak Gas Services. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Kodiak Gas Services compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Kodiak Gas Services's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Kodiak Gas Services's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/KGS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Kodiak Gas Services analyst ratings.</strong></a></p>
<h2>Delving into Kodiak Gas Services's Background</h2>
<p>Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. It manages business through two operating segments namely Compression Operations and Other Services. Compression Operations consist of operating company-owned and customer-owned compression infrastructure for customers, pursuant to fixed-revenue contracts to enable the production, gathering and transportation of natural gas and oil. Other Services consist of a full range of contract services to support the needs of customers, including station construction, maintenance and overhaul and other ancillary time and material-based offerings.</p>
<h3>Kodiak Gas Services's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Kodiak Gas Services displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>52.31%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>2.17%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>0.55%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Kodiak Gas Services's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.17%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>1.95</strong>, Kodiak Gas Services faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Closer Look at 5 Analyst Recommendations For Kodiak Gas Services

<p>Coursera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $14.89, along with a high estimate of $22.00 and a low estimate of $9.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 4.31%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726750819_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of Coursera among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nafeesa Gupta</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$11.00</td>
<td>-</td>
</tr>
<tr>
<td>Brett Knoblauch</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Jeffrey Silber</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$11.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$9.00</td>
<td>$10.50</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Sarang Vora</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Jason Celino</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Sarang Vora</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Coursera. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Coursera compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Coursera's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Coursera's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/COUR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Coursera analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Coursera</h2>
<p>Coursera Inc is an online learning platform that connects learners, educators, and institutions with the goal of providing educational content that is affordable, accessible, and relevant. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The company operates through three reporting segments: Consumer, Enterprise, and Degrees. The majority of revenue is generated from the Consumer segment. The consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers.</p>
<h3>A Deep Dive into Coursera's Financials</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Coursera's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately <strong>10.82%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Coursera's net margin excels beyond industry benchmarks, reaching <strong>-13.49%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-3.85%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-2.52%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Coursera's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.0</strong>.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


COUR

Demystifying Coursera: Insights From 9 Analyst Reviews

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Globus Medical (GMED – Research Report), Novo Nordis...

Wall Street Analysts Are Bullish on Top Healthcare Picks

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Investing guru Cathie Wood sees precision therapeutics as a massive growth market. She forecasts sales in the category can grow by a compound annual growth rate (<span>CAGR</span>) of 30% through 2030. Efficiencies could <a href="https://assets.arkinvest.com/media-8e522a83-1b23-4d58-a202-792712f8d2d3/3ca398a4-8e1d-41f9-9868-0b6002a9d191/ARK-Invest_Big-Ideas-2024_FINAL.pdf">contribute $1.5 trillion</a> to the enterprise value of companies pursuing these technologies.</p>



<p>Over the next five years or so, gene-editing using CRISPR-based processes to target and cure rare diseases and chronic conditions will expand at a 46% CAGR.</p>



<p>Wood seeks out opportunities to generate phenomenal returns by buying representative stocks early and watching them evolve. While that means her returns in the gene-editing field may lag the market indexes for a time, the investing guru has a much longer investment horizon. You should too.</p>



<p>Buying the <a href="https://investorplace.com/2024/07/the-top-3-cathie-wood-stocks-to-buy-now-summer-2024/">best gene-editing stocks</a> shouldn&rsquo;t be thought of as a get-rich-quick scheme. It will take years for the companies using and pursuing these technologies to achieve full valuation. But adding the best gene-editing stocks to your portfolio now gives you the chance to ensure tremendous returns down the road. Here are three stocks to buy today.</p>



<h2>CRISPR Therapeutics (CRSP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/11/crispr-theraputics-crsp-stock-1600-300x169.jpg" alt="the CRISPR Therapeutics (CRSP) logo seen displayed on a smartphone"><div>Source: rafapress / Shutterstock.com</div></div><p>Any discussion of CRISPR-based technology has to begin with <strong>CRISPR Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/crsp-stock-quote/"><strong>CRSP</strong></a></span>), the leading player in the space.</p>



<p>Otherwise known as Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR directs the programmable enzyme Cas9 to <a href="https://investorplace.com/2024/07/the-top-3-cathie-wood-stocks-to-buy-now-summer-2024/">cleave DNA with extreme precision</a> in virtually any organism. CRISPR Therapeutics is using the procedure to develop cutting-edge therapies to target rare diseases.&nbsp;</p>



<p>It is not an overnight success, though after developing its first successful treatment targeting rare blood diseases, it may look that way. CRISPR&rsquo;s Casgevy is for patients with transfusion-dependent beta-thalassemia (<span>TDT</span>) and sickle cell disease (<span>SCD</span>).</p>



<p>TDT is a <a href="https://www.biospace.com/thalassemia-market-size-to-reach-usd-3-0-billion-by-2034-impelled-by-several-novel-medications#:~:text=The%20thalassemia%20market%20size%20reached,3.84%25%20during%202024%2D2034.">$3 billion market opportunity</a> that could grow to $4 billion by 2034. The National Institute of Health says the rare hereditary blood disorder <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429534/">affects approximately 2,000 individuals</a> in the U.S. CRISPR has <a href="https://investorplace.com/2023/08/got-600-here-are-3-no-brainer-stocks-you-absolutely-must-buy/">partnered with the much larger</a> <strong>Vertex Pharmaceuticals</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/vrtx-stock-quote/"><strong>VRTX</strong></a></span>) to market Casgevy.</p>



<p>The therapy received Food and Drug Administration approval only in December, and CRISPR has already <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1674416/000095017024055689/crsp-20240508.htm">activated 25 treatment centers</a> globally to treat patients. The drug can only be administered in authorized facilities after first collecting cells from the patient. CRISPR reported that it has begun that process with multiple patients.</p>



<p>Although the biotech will only receive 40% of the revenue Vertex generates from marketing the therapy, look for CRISPR Therapeutics to see sales grow. Especially as it has a robust pipeline, this is one of the best gene-editing stocks to buy.&nbsp;</p>



<h2>Silence Therapeutics (SLN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/10/lab-300x169.jpg" alt="Scientists in a lab"><div>Source: Matej Kastelic / Shutterstock</div></div><p>Gene silencing is a new treatment technique that uses the body&rsquo;s <a href="https://silence-therapeutics.com/patients/gene-silencing-explained/gene-silencing-the-basics/default.aspx">natural suppression of gene expression</a>, or &ldquo;silencing&rdquo; it, to treat diseases. While gene therapy is more widely known, silencing has distinct advantages. It does not introduce new genes into the body but rather uses already -existing biological processes to treat a disease.</p>



<p><strong>Silence Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/sln-stock-quote/"><strong>SLN</strong></a></span>) is a leader in RNA silencing or interference. Because our bodies already naturally perform the task of defending against viruses or controlling gene activity, silencing is a safer and reversible process should there be an adverse reaction.</p>



<p>Silence Therapeutics recently reported that its lead drug candidate, zerlasiran (SLN360), <a href="https://investorplace.com/2024/07/morgan-stanley-predicts-triple-digit-rally-for-these-3-stocks/">achieved positive results</a> during Phase 2 clinical trials. The therapy targets patients with a high risk of atherosclerotic cardiovascular disease.</p>



<p>With the stock market crashing, Silence Therapeutics stock is tumbling into negative territory for the year but is still up over 150% over the last 12 months. Investors should take advantage of the discount the market is offering to buy this top gene-editing stock.</p>



<h2>Alnylam Pharmaceuticals (ALNY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/alny1600-300x169.png" alt="Illustrative Editorial of Alnylam Pharmaceuticals Inc website homepage. Alnylam Pharmaceuticals Inc logo visible on display screen. ALNY stock"><div>Source: Pavel Kapysh / Shutterstock.com</div></div><p><strong>Alnylam Pharmaceuticals</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/alny-stock-quote/"><strong>ALNY</strong></a></span>) is another biotech pursuing RNA interference (RNAi) therapies. Its vutrisiran is a treatment for a rare, aggressive heart condition called transthyretin amyloid cardiomyopathy (ATTR&#8209;CM). In late-stage trials, vutrisiran recently reported positive Phase 3 results.</p>



<p>Marketed as Amvuttra, vutrisiran was shown to cut the risk of death from ATTR-CM by more than a third. It targets a protein made in the liver called prealbumin and, using RNAi, seeks to neutralize the gene&rsquo;s expression.&nbsp;</p>



<p>CEO Yvonne Greenstreet <a href="https://firstwordpharma.com/story/5869456">called the late-stage results</a> a &ldquo;home run.&rdquo; She believes vutrisiran puts in Alnylam Pharmaceuticals&rsquo; &ldquo;hands a multibillion-dollar opportunity.&rdquo; It means the biotech has a <a href="https://investorplace.com/2024/07/alnylam-stock-is-a-blockbuster-biopharma-in-the-making/">blockbuster in the making</a>.</p>



<p>Alnylam just reported strong second-quarter results with Amvuttra sales driving 34% year-over-year revenue growth to $410 million. Amvuttra <a href="https://alnylampharmaceuticalsinc.gcs-web.com/static-files/52c713b4-aead-430c-b2ec-f92b47d4783b">represented 56% of total sales</a>, or $230 million. If vutrisiran gets FDA approval, investors could see revenue rocket to new heights, making it one of the best gene-editing stocks to buy.</p>



<p><em>On the date of publication, Rich Duprey did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.</em></p>



<p><em>On the date of publication, the responsible editor did not have (either directly or<br>indirectly) any positions in the securities mentioned in this article</em>.</p>
<div><p>Rich Duprey has written about stocks and investing for the past 20 years. His articles have appeared on Nasdaq.com, The Motley Fool, and Yahoo! Finance, and he has been referenced by U.S. and international publications, including MarketWatch, Financial Times, Forbes, Fast Company, USA Today, Milwaukee Journal Sentinel, Cheddar News, The Boston Globe, L&rsquo;Express, and numerous other news outlets.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
<p>The post <a href="https://investorplace.com/2024/08/the-3-best-gene-editing-stocks-to-buy-in-august-2024/">The 3 Best Gene Editing Stocks to Buy in August 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

The 3 Best Gene Editing Stocks to Buy in August 2024

Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential

Crispr Therapeutics AG (CRSP – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Silvan Tuerkc...

Crispr Therapeutics AG: Strategic Progress and Strong Financials Bolstering a Buy Rating

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>With the market struggling amid rising recession fears, now may be the ideal time to consider <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a>. First, the sector itself is a financially lucrative one. Last year, the ecosystem <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">reached a valuation of $1.55 trillion</a>. Between 2024 to 2030, the segment could expand at a compound annual growth rate (CAGR) of 13.96% to $3.88 trillion.</p>



<p>Along this line of thinking, the current market fallout makes biotech stocks all the more intriguing. No matter what, society will always push for solutions that address the human condition. From cancer to autoimmune diseases and other conditions and ailments, the search for effective treatments is a perpetual one. Not only that, a healthy society is an economically productive and efficient one.</p>



<p>Therefore, it&rsquo;s no surprise that government support and incentives underline various biotech-related initiatives. It&rsquo;s in all of our best interests to promote overall wellness. And in that sense, the narrative is recession resistant. With that in mind, below are biotech stocks you can now pick up on a relative discount.</p>



<h2>Crispr Therapeutics (CRSP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/crispr_crsp1600-300x169.jpg" alt="CRISPR (CRSP) logo within a DNA sequence"><div>Source: Catalin Rusnac/ShutterStock.com</div></div><p>One of the most groundbreaking innovators among biotech stocks, <strong>Crispr Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/crsp-stock-quote/"><strong>CRSP</strong></a>) specializes in gene-editing therapies. Primarily, the company&rsquo;s CRISPR/Cas9 platform &ndash; a genome-editing technology that allows scientists to precisely alter DNA &ndash; may have the potential to cure various genetic disorders. Crispr aims to do so by essentially fixing faulty genes.</p>



<p>While CRSP stock is certainly enticing, its main challenge is profitability (or lack thereof). In the past year since the second quarter, Crispr posted an average loss per share of 81 cents. Now, in Q4 of last year, it posted earnings per share of $1.10, beating the expected loss of 7 cents. That demonstrates that Crispr has potential &ndash; it just needs to demonstrate this more often.</p>



<p>Right now, it&rsquo;s not the most attractively priced security, trading hands at 14.7x trailing-year sales. In contrast, the biotech sector&rsquo;s <a href="https://fullratio.com/ps-ratio-by-industry">average revenue multiple sits at 6.23x</a>. Still, in the past year, CRSP&rsquo;s average price-to-sales ratio stood at 27.09.</p>



<p>After a potentially rough outing in fiscal 2024, the following year could see <a href="https://finance.yahoo.com/quote/crsp/analysis">sales rise to $332.54 million</a>, with a blistering high-side estimate of $3.31 billion.</p>



<h2>Voyager Therapeutics (VYGR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1726134715-300x169.png" alt="Biochemical/biotech research scientist team working with microscope"><div>Source: Mongkolchon Akesin / Shutterstock.com</div></div><p>Focused on the development of gene therapies for severe neurological diseases, <strong>Voyager Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/vygr-stock-quote/"><strong>VYGR</strong></a>) represents one of the top biotech stocks to consider. Its lead candidate is VY-TAU01, which is an anti-tau antibody program for the treatment of Alzheimer&rsquo;s disease. In its pipeline, it also features a gene therapy that addresses amyotrophic lateral sclerosis or ALS.</p>



<p>As with other biotech stocks, Voyager has trouble with generating consistent profitability. True, in Q4, the company posted EPS of $1.25. This dramatically exceeded the consensus target calling for a loss of 29 cents per share. However, the company has struggled in other quarters to print positive results. That also didn&rsquo;t change with the <a href="https://investorplace.com/earning-results/2024/08/vygr-stock-earnings-voyager-therapeutics-for-q2-of-2024/">latest Q2 results</a>.</p>



<p>At the moment, VYGR stock trades hands at 3.23x sales. While that seems undervalued, it&rsquo;s a deceptive figure since analysts are projecting that by the end of this year, sales may land at $48.51 million. If so, that would imply an 80.6% drop from last year&rsquo;s tally of $250.01 million.</p>



<p>However, because of the demand for treatment solutions for neurological diseases, VYGR stock is worth keeping on your watchlist.</p>



<h2>Sarepta Therapeutics (SRPT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/08/genetics-dna-flgt-1600-300x169.jpg" alt="a visualization of DNA in a vial. TSHA stock"><div>Source: Connect world / Shutterstock.com</div></div><p>A specialist in the field of precision genetic medicine, <strong>Sarepta Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/srpt-stock-quote/"><strong>SRPT</strong></a>) focuses on rare neuromuscular diseases. In particular, its RNA-targeted therapies and gene therapies provide hope for patients suffering from conditions such as Duchenne muscular dystrophy. While SPRT stock has been a strong performer this year, the market fallout has negatively impacted the company&rsquo;s valuation.</p>



<p>Curretnly, SRPT stock trades hands at 9.53x sales. That&rsquo;s a modest discount compared to the prior year&rsquo;s average multiple of 9.57x. Further, it&rsquo;s elevated compared to the industry average. However, it&rsquo;s worth pointing out that in fiscal 2024, analysts <a href="https://finance.yahoo.com/quote/srpt/analysis">project sales to hit $2.02 billion</a>. If so, this figure would represent a 62.6% lift from the prior year&rsquo;s haul of $1.24 billion. In addition, the high-side estimate calls for $2.32 billion.</p>



<p>Assuming a shares outstanding count of 94.52 million, SRPT is currently trading at around 5.73x projected high-side revenue. It&rsquo;s more than possible that Sarepta could hit that target considering that in fiscal 2025, the consensus view for sales calls for $3.27 billion. With so much excitement built into this space, SRPT ranks among the biotech stocks to buy.</p>



<h2>Regenxbio (RGNX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600-300x169.png" alt="Biotechnology stocks, biomedical stocks"><div>Source: aslysun / Shutterstock.com</div></div><p>Another gene-therapy focused enterprise, <strong>Regenxbio</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgnx-stock-quote/"><strong>RGNX</strong></a>) is a clinical-stage biotech that utilizes a proprietary platform called NAV Technology. This platform enables Regenxbio to develop advanced therapeutic candidates for vexing conditions such as wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases. It also features solutions for other conditions such as muscular dystrophy.</p>



<p>Coming upon a familiar theme among biotech stocks, Regenxbio has trouble with consistent profitability. In the past year since Q2, the company incurred a loss per share of $1.32. That said, analysts anticipated a loss of $1.34 during the same period. Therefore, the biotech managed to post a modest &ldquo;earnings&rdquo; surprise of 0.92%.</p>



<p>Right now, RGNX stock trades hands at 6.47x sales. That&rsquo;s roughly in line with the industry average. However, it&rsquo;s noticeably lower than the prior year&rsquo;s average multiple of 7.86x. Analysts see modest growth this year. However, in fiscal 2025, sales could soar to $249.2 million, a far cry from last year&rsquo;s print of $90.24 million.</p>



<h2>Blueprint Medicines (BPMC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/05/nktx_cancerresearch1600-300x169.png" alt="DNA strand and Cancer Cell Oncology Research Concept 3D rendering. LIXT Stock"><div>Source: CI Photos / Shutterstock.com</div></div><p>Another specialist in the field of precision medicine, <strong>Blueprint Medicines</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/bpmc-stock-quote/"><strong>BPMC</strong></a>) focuses on specific groups of cancers and rare diseases. It&rsquo;s potentially one of the groundbreaking biotech stocks thanks to the underlying targeted approach to cancer treatment. Essentially, Blueprint designs therapeutics based on the specific genetic mutations catalyzing the disease, potentially improving efficacy and reducing complications.</p>



<p>As with other biotech stocks, Blueprint is sporadic in terms of its bottom line. In the past year since Q2, the company posted an average loss per share of 86 cents. In Q1, it managed to deliver EPS of $1.40, far exceeding the expected loss of $1.66. However, investors will eventually want to see more of these positive figures.</p>



<p>Now, BMPC stock is risky, trading hands at 16.06x sales. That&rsquo;s a screaming hot premium. But to be fair, in the prior year, the average multiple stood at 21.41x. The kicker, though, is the fiscal 2024 forecast. Experts believe that revenue could jump to $491.86 million. If so, that would imply a near doubling from last year&rsquo;s print of $249.38 million.</p>



<h2>Precision BioSciences (DTIL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/gene-edit-300x169.png" alt="An image of a scientist holding forceps, taking a piece of a DNA helix"><div>Source: Panuwach/Shutterstock</div></div><p>A biotechnology firm focused on the genome editing, <strong>Precision BioSciences</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/dtil-stock-quote/"><strong>DTIL</strong></a>) utilizes a proprietary platform called ARCUS to develop therapies for genetic diseases and cancer. Theoretically, this unique platform enables Precision to design highly specified genetic modifications. This process can potentially lead to more effective and safer therapies.</p>



<p>Unlike many other biotech stocks in its class, Precision has started to generate consistent profits. In the second half of 2023, the company incurred an average loss per share of $3.08. However, in the first half of this year, the average EPS stands at almost $3.19. In the past four quarters, the average EPS is 5 cents, yielding an earnings surprise of 139.8%.</p>



<p>Enticingly, shares trade hands at only 0.51x sales. What&rsquo;s more, in the prior year, the market accepted a multiple of 1.1x. Therefore, DTIL stock potentially has room to run. That&rsquo;s exactly what analysts are anticipating, projecting that fiscal 2024 sales may hit $72.47 million. That&rsquo;s up 48.7% from last year&rsquo;s tally of $48.73 million.</p>



<h2>Allogene Therapeutics (ALLO)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/04/allogene.jpg"><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/04/allogene-300x169.jpg" alt="The logo for Allogene Therapeutics Inc (ALLO) is displayed on a building front."></a><p>A clinical-stage immuno-oncology firm, <strong>Allogene Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/allo-stock-quote/"><strong>ALLO</strong></a>) develops and commercializes genetically engineered allogeneic T-cell therapies for the treatment of cancer. Specifically, its platform targets pediatric and adult patients suffering from leukemia. According to its website, one of Allogene&rsquo;s core advantages is its scalable and efficient manufacturing process. This attribute enables potentially lifesaving care at reduced cost, holistically easing the burden of treatment.</p>



<p>Allogene isn&rsquo;t a profitable enterprise so it will require significant patience &ndash; more so than many other biotech stocks. In addition, the company doesn&rsquo;t generate much in terms of revenue. Last year, the company posted only $95,000 on the top line. What&rsquo;s worse, by the end of the current year, analysts believe that sales could dip to $50,000.</p>



<p>So, why bother with ALLO stock? Aside from the groundbreaking treatment potential, covering experts believe that by fiscal 2025, revenue could soar to $4.1 million. Further, the high-side estimate calls for $60.97 million.</p>



<p>Interestingly, assuming a shares outstanding count of 208.78 million, ALLO stock is trading at 8.53x projected high-side 2025 revenue. That&rsquo;s not bad considering the therapeutic potential.</p>



<p><em>On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>



<p><em>On the date of publication, the responsible editor held a LONG position in CRSP.&nbsp;</em></p>
<div><p>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
<p>The post <a href="https://investorplace.com/2024/08/7-biotech-stocks-to-buy-for-their-game-changing-potential/">7 Biotech Stocks to Buy for Their Game-Changing Potential</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Biotech Stocks to Buy for Their Game-Changing Potential

BofA upgrades Editas to buy, cites reni-cel progress

Truist Financial analyst Joon Lee maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target of $100.0...

Crispr Therapeutics AG (CRSP) Receives a Buy from Truist Financial

Crispr's Casgevy Launch: Promising Start, Uncertain Future

Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres

Crispr Therapeutics: Prepare To Be Bored

ALLO

BLUE

DTIL

EDIT

GMED

RGNX

SRPT

VRTX

VYGR

Press Releases

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference

Health Care

CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach

Earnings

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference

CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

CRISPR Therapeutics

CRISPR Therapeutics (CRSP) Forecast

CRISPR Therapeutics (NASDAQ:CRSP) Stock, Quote.Headers.trade-ideas